Going Below The Surface E-newsletter: December 2020
December 18, 2020
As 2020 draws to a close, it will be a year we’ll never forget, though we wish we could. We’d like to pause and reflect on the many things we can be thankful for, and on the hope that the next year holds with the distribution of COVID-19 vaccines.
We wish all of you a safe, healthy and restful holiday season.
In two articles, we examine the state of our health spending and potential solutions to more sustainably fund the innovative treatments and cures we need.
Preserving and Funding the Next Phase of Innovation
Now, more than ever, we are witnessing just how transformative biomedical innovation can be for society. Our hopes for returning to “normal” life – businesses fully open, travel, plays and movies in theaters, fans in sports arenas, hugging friends we haven’t seen in a while – hinges in large part on a COVID-19 vaccine. The arrival of these vaccines reminds us how important it is that our health system maintains structural incentives for these groundbreaking developments to become reality.
Typically, some of the insurance premiums we pay partially fund new health care technologies and devices. But with health care expenditures projected to reach 20% of our GDP in the next decade, how sustainable is this system?
Before the onset of the pandemic, the National Pharmaceutical Council conducted a survey to assess U.S. payers’ and consumers’ willingness to pay for new therapies for chronic adult, pediatric or geriatric populations as well as rare diseases. The results? Neither the payers nor the consumers wanted a 5% increase even if it supported access to new health technologies that would improve outcomes and quality of life.
Why it Matters: Employers and consumers want access to new health care treatments and technologies, but the evidence shows they no longer want to continue to bear that cost burden. Given continually increasing premiums, it is no wonder these stakeholders feel tapped out. We know innovation is essential, so where do we go from here to make sure we have it?
As policymakers consider how to keep costs in check, we must ensure that any effort considers the value treatments deliver for patients and society overall. Sadly, low-value care plagues our health system, draining limited dollars to pay for services that do not provide patients with real value. The good news is that there is significant support for treatments that make broad improvements in public health, although respondents were not very willing to pay more for it. The NPC survey found that respondents were more willing to pay for new medical technologies for common adult diseases, such as diabetes and heart disease, compared to less common pediatric or geriatric conditions. We must find ways to devote resources to high-value care and protect incentives for innovation that help vulnerable and disenfranchised groups, instead of continuing to do the unsustainable: push costs onto employers and consumers.
After COVID, the Work Continues
According to the latest National Health Expenditure data released Dec. 16 by the Centers for Medicare and Medicaid Services, health spending grew by 4.6% in 2019. It is not surprising that costs continued to rise in 2019, as these numbers do not reflect the COVID-19 pandemic. A recent article from the Kaiser Family Foundation revealed that in 2020, health services revenues have fallen by 2.4% compared to last year. Ambulatory care settings such as physician offices and outpatient care centers saw the largest drop in utilization (4% and 4.7%, respectively). Though the use of telehealth rapidly increased, it did not make up for the loss of in-person visits.
No one should celebrate reducing health spending this way, because it means patients are skipping important care. As of late April, according to an analysis by Epic Health Research Network, cancer screening rates have fallen rapidly, with patients more hesitant to leave home due to COVID-19. A follow-up review by the organization estimated there has been 285,000 missed breast cancer screenings, 95,000 missed colon cancer screenings, and 40,000 missed cervical cancer screenings so far in 2020.
Why It Matters: A reduction in overall care does not necessarily translate to the elimination of low-value care. Due to the pandemic, patients opted out of both necessary and unnecessary services. While a decrease in low-value care services is a step in the right direction, missed high-value care services such as cancer screenings will have long term impacts on our system, and more importantly, on patient outcomes. As our health system recovers from this public health crisis, we must continue to persuade clinicians and policy makers to stay focused on optimizing our system to promote high-value care.